Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 569
0
Funds holding %
of 6,814 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 23
8% more funds holding
Funds holding: 254 [Q2] → 274 (+20) [Q3]
4% more capital invested
Capital invested by funds: $3.32B [Q2] → $3.45B (+$136M) [Q3]
2% more call options, than puts
Call options by funds: $95.7M | Put options by funds: $94M
5.89% less ownership
Funds ownership: 86.83% [Q2] → 80.94% (-5.89%) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 93
27% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$116
30%
upside
Avg. target
$134
51%
upside
High target
$180
102%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia 34% 1-year accuracy 56 / 166 met price target | 49%upside $133 | Buy Reiterated | 13 Jan 2025 |
Truist Securities Joon Lee 50% 1-year accuracy 20 / 40 met price target | 102%upside $180 | Buy Maintained | 13 Jan 2025 |
Mizuho Graig Suvannavejh 40% 1-year accuracy 12 / 30 met price target | 37%upside $122 | Outperform Maintained | 31 Dec 2024 |
Cantor Fitzgerald Charles Duncan 43% 1-year accuracy 35 / 82 met price target | 36%upside $121 | Overweight Reiterated | 12 Dec 2024 |
Baird Joel Beatty 48% 1-year accuracy 20 / 42 met price target | 30%upside $116 | Outperform Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 6 articles about AXSM published over the past 30 days
Positive
Seeking Alpha
1 week ago
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, supporting a bullish outlook.
Positive
Benzinga
1 week ago
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.
Negative
Investors Business Daily
2 weeks ago
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. The post Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation appeared first on Investor's Business Daily.
Negative
Benzinga
2 weeks ago
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.
Positive
Reuters
2 weeks ago
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
Neutral
GlobeNewsWire
2 weeks ago
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
Negative
Zacks Investment Research
1 month ago
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Positive
Seeking Alpha
1 month ago
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters.
Positive
Benzinga
1 month ago
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial.
Positive
Zacks Investment Research
2 months ago
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Charts implemented using Lightweight Charts™